55608Facilitating the adoption of a new bladder cancer diagnostic test to support the management of urology waiting times post-COVID-19 lockdownClosedFeasibility StudiesInnovate UKThis project will focus on the introduction of a novel technology to assist NHS in the stratification of urology patients (to ensure a quick diagnosis of patients at highest risk of having a bladder tumour). In the aftermath of COVID-19, patients presenting to NHS urology clinics will not be able to be prioritised with current tools. Arquer Diagnostics have a new Bladder Cancer Test (ADXBLADDER) which can be used to support the stratification of patients', thanks to its ability to rule out high risk tumours with a 98.7-99% certainty. Those patients with a negative test result have a very low chance of having a high risk tumour meaning they can safely delay having the invasive tests at the urology clinics, whilst those at high risk can be prioritised. Through this project a clinical team will be deployed by Arquer Diagnostics to identify those hospitals most in need of this stratification tool and to provide technical expertise for the installation of the test into NHS diagnostic laboratories. The team will also disseminate the relevant clinical and technical information to the NHS Urologists. These activities will provide NHS with a reliable stratification tool so that all the patients delayed during the COVID-19 crisis will be attended to with a strong clinical rationale, reducing the delay faced by those patients at highest risk, allowing these high risk tumours to be identified earlier and therefore improving their outcome. Additional funding will allow Arquer to design and conduct a survey of 50 urologists and 20 bladder cancer patients to understand the desire and willingness to use ADXBLADDER and to understand how differently urologists and patients view the technology. The results of this survey will allow Arquer to ensure that the evidence available for the test is presented in a way that demonstrates the greatest value of ADXBLADDER to both urologists and patients alike. This will ensure that when ADXBLADDER is assessed by NICE, the evidence supports this, which will facilitate the eventual adoption of the technology,